Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aditxt, Inc. ( (ADTX) ) has shared an announcement.
Aditxt, Inc.’s subsidiary, Adimune, Inc., has completed preclinical studies for its ADI-100 immune modulation therapy, positioning it for human trials targeting Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome. ADI-100 demonstrated efficacy in autoimmune disease models, restoring immune tolerance without impairing overall immune responsiveness, and is set to transform the autoimmune treatment landscape with its innovative approach.
More about Aditxt, Inc.
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations and operates within an ecosystem of research institutions, industry partners, and shareholders to address significant societal challenges. The company currently focuses on immune health and precision health, with plans to expand into public and women’s health through strategic partnerships and mergers.
YTD Price Performance: -99.87%
Average Trading Volume: 2,891,173
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.07M
For an in-depth examination of ADTX stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
